Found: 3
Select item for more details and to access through your institution.
RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.
- Published in:
- Allergy, 2022, v. 77, n. 9, p. 2848, doi. 10.1111/all.15382
- By:
- Publication type:
- Article
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.
- Published in:
- Clinical & Experimental Allergy, 2024, v. 54, n. 4, p. 286, doi. 10.1111/cea.14436
- By:
- Publication type:
- Article
Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
- Published in:
- International Archives of Allergy & Immunology, 2020, v. 181, n. 8, p. 613, doi. 10.1159/000508559
- By:
- Publication type:
- Article